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Surveillance is a new management option for small renal masses (SRMs) in aged and inﬁrm patients with short-life expectancy.
The current literature on surveillance of SRM contains mostly small, retrospective studies with limited data. Imaging alone is
inadequate for suggesting the aggressive potential of SRM for both diagnosis and followup. Current data suggest that a computed
tomography (CT) or magnetic resonance imaging (MRI) every 3 months in the 1st year, every 6 months in the next 2 years, and
every year thereafter, is appropriate for observation. The authors rather believe in active surveillance with mandatory initial and
followup renal tumor biopsies than classical observation. Since not all SRMs are harmless, selection criteria for active surveillance
need to be improved. In addition, there is need for larger studies in order to better outline oncological outcome and followup
protocols.
Copyright © 2008 Mehmet Ozsoy et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
During the last 20 years, the incidence of renal cell cancer
(RCC) has been steadily increasing (2-3%/year) [1]. This
rise is mostly due to the increase in detection of incidental
small renal masses (SRM ≤ 4cm) by widespread use of
cross-sectional imaging techniques such as ultrasonogra-
phy (USG), computed tomography (CT), and magnetic
resonance imaging (MRI). Between 1983 and 2002, the
detection of SRM showed almost a three-fold increase
for tumors <2cm and 2–4cm, respectively, whereas the
detection rate of 4–7cm and >7cm just rose by 50% and
26%, respectively [2]. Nowadays, more than 50% of all renal
tumors are SRM [3]. The majority of these tumors are
asymptomatic and carry a good prognosis [4]. For open and
laparoscopic nephron-sparing surgery (NSS), 5-year cancer-
speciﬁc survival rates of 96–100% have been reported [5, 6].
The highest incidence of incidentally detected SRM is
seen in elderly patients [4], who usually present with a
number of comorbidities [7–9]. To manage these patients, a
variety of treatment options have evolved in the past several
years ranging from radical nephrectomy to observation for
SRM. NSS remains the standard of care for small RCC,
but minimal-invasive therapies and surveillance evolved as
alternative treatment options. Here, we review the literature
on surveillance for the management of SRM.
2. ARE SMALL RENAL MASSES ALWAYS MALIGNANT?
Up to 20% of SRM are actually benign [10–12]. Unfortu-
nately, tumor size alone does not appear to be a predictor of
benign or malignant tumor biology. Frank et al. retrospec-
tively examined 2935 solid renal tumors at all sizes treated
over a 25-year period and reported 46.3%, 22.4%, 22%,
and 19.9% of renal lesions lower than 1cm, 2cm, 3cm,
and 4cm to be benign, respectively [12]. In the prospective
randomized multicenter EORTC 30904 study, comparing
nephron-sparing surgery with nephrectomy in patients with
resectable RCC, 11.6% of the 541 surgically removed tumors
(≤5cm) were benign [13] and among the 100 lesions
(mean diameter 2.8cm) on which Gill et al. [14]p e r f o r m e d
laparoscopic partial nephrectomy 30% were identiﬁed as
benign. In a recent report by Remzi et al. [11] that reﬂects
t h er e n a lt u m o r so ft o d a y ,r e n a lt u m o r so f≤2cm, 2-3cm,
3-4cm were reported to be benign in 24.6%, 20.4%, and
16.0%, respectively, without any correlation to tumor size
(P = .66). In another series of 1208 SRM, the frequency of
benign lesions in the tumor size ranges 0.1–1.0, 1.1–2.0, and
2.1–3.0 was 15%, 14%, and 14%, respectively. However, the
incidence of benign lesions decreased signiﬁcantly in tumors
measuring 3.1–4.0cm(8%,P = .001) [10].
Benignlesions(oncocytomas,low-fatangiomyolipomas)
are still diﬃcult to diﬀerentiate from RCC’s even with2 Advances in Urology
today’s advanced imaging modalities. In a recent study
by Remzi et al. [3], only 17% of all benign lesions were
correctly identiﬁed as benign on preoperative CT and 43%
of patients who were assessed incorrectly on preoperative
CT’s underwent unnecessary radical surgery. There are only
a few studies pointing out the success of diﬀerentiating low-
fat AML from RCC with nonroutine special imaging studies
[15].
In addition to initial tumor size, growth rate of tumors
on surveillance is also not a reliable predictor of histology. In
their review, Chawla et al. compared initial tumor size and
the observed growth rate between oncocytomas and RCC
variants. Of the 76 tumors, 12% were oncocytomas and the
remaining 88% were RCC. At ﬁrst presentation, mean tumor
sizes were 2.00 ± 0.99 (median 1.50, ranging from 1 to 3.9)
and 2.21±1.5cm (median 2.0, ranging from 0.20 to 12.0) in
oncocytomas and RCC’s, respectively, (P = .59). The mean
growth rate of oncocytomas and RCC variants did not diﬀer
statistically (0.05 ± 0.67, median 0.16, ranging from 1.62 to
0.62, and 0.35 ± 0.41cm yearly, median 0.35, ranging from
0.42 to 1.6, respectively, P = .15) [8]. Thus growth rate after
opting for surveillance strategy is not an ideal parameter to
further initiate surgical treatment [12–14].
3. ARESMALLRENALCELLCARCINOMASHARMLESS?
In their study, Remzi et al. [11] retrospectively analyzed 287
SRMs that were deﬁned to be ≤4cm by preoperative CT
scans and subsequently underwent surgery. About 80% of
these lesions were malignant. Tumors were stratiﬁed into
three groups according to their largest diameter, deﬁned
as ≤2cm, 2.1 to 3.0cm and 3.1 to 4.0cm. They were also
groupedintotwogroupsof ≤3cmand3.1to4cm.Therewas
a signiﬁcant correlation between tumor size and Fuhrman
grade. Two (4.2%), four (5%), and twenty ﬁve (25.5%) cases
of RCC 2cm or less, 2.1 to 3cm, and 3.1 to 4cm in diameter
had Fuhrman grade G3/4, respectively, (P = .0007). but
there was no statistical diﬀerence in Fuhrman grades G3/4
between those ≤2a n d2 . 1t o3 c m( P = .847), whereas
the diﬀerence between ≤3c ma n d3 . 1t o4w a ss t a t i s t i c a l l y
signiﬁcant (P=. 0023). Advanced stage (pT3a or greater)
was documented in two (4.2%), 12 (14.9%) and 35 (35.7%)
cases for RCC diameter ≤2cm, 2.1 to 3.0cm and 3.1 to
4cm,respectively ,(P=. 0023). At least pT3a stage showed no
statistical diﬀerence between ≤2c ma n d2 . 1t o3c mg r o u p
(P=. 172) whereas the diﬀerence between ≤3cmand3.1to
4cm groups was statistically signiﬁcant (P=. 0007). Among
the 287 patients, 14 present with distant metastases, 10 of
which being among the 119 tumors within the 3.1 to 4cm
group (8.4%) and the remaining four among the 168 tumors
of ≤3cm group (2.4%) (P=. 0045). This study showed a
high-aggressive potential of SRM beyond 3cm, and thus not
all SRM are actually harmless [11].
Klatte et al. [10] investigated 1208 patients with SRM,
of whom 88% had RCC. Mean tumor size (±SD) was 2.9
(±0.9) cm. In their study, cancer-speciﬁc survival of small
nonmetastatic (NX/N0M0) RCC was 96% and 91% after
5 and 10 years, respectively. There was a 7% chance of
RCC recurrence post nephrectomy at 5 years. Independent
prognostic factors of cancer-speciﬁc survival were ECOG
performance status, T stage, presence of metastatic disease,
and Fuhrman nuclear grade. This study pointed out that
there is a small but not insigniﬁcant number of patients who
recur after curative surgery for SRM.
Measuring tumor diameters by sequential imaging
modalities are also not reliable, so when choosing surveil-
lance as an option the cut-oﬀ diameter should be set well.
As stated above, SRM with a tumor diameter below 3cm on
CT seems to ﬁt better for surveillance than larger tumors. In
addition to size, patients with concomitant invasion of the
perirenal fat (clinical T3a) on cross-sectional imaging should
be excluded from a surveillance protocol, since T3a tumors
are at a higher risk of RCC-speciﬁc death [10].
In their study, Minardi et al. warn against the possibility
of recurrence and death in patients even with low-grade
RCC’s. They report on 48 patients with pT1a clear cell RCC
who underwent NSS. After a median followup of 2 years,
3.9% had died of metastatic RCC. Thus even small lesions
can metastasize [16].
4. NEW TREATMENT OPTIONS
Nowadays, NSS is the standard treatment for SRM, which
is related to the minimal impairment of renal function and
excellent cancer-speciﬁc survival rates either in open and
laparoscopic NSS of about 96–100% after 5 years [5, 6].
Recently minimal invasive therapy modalities such
as radiofrequency ablation (RFA), High-intensity focused
ultrasound (HIFU) and cryotherapy emerged as potential
treatment options for clinically localized RCC for SRM
with promising short-term results [17]. Eﬀective renal
cryoablation has been achieved by open and laparoscopic
approaches as well as by percutaneous image-guided tech-
niques. Percutaneous RFA has been successfully performed
under ultrasound, CT, or MRI guidance [18]. Many studies
report excellent cancer-speciﬁc survival rates of 90–100%
[18, 19], however most of the series do not describe
the underlying tumor entity (e.g., benign/malignant), have
small number of patients treated and a short followup.
Additionally Klingler et al. recently reported that skipping
(up to 24%) was a major problem in RFA [20]. It is
well known from series of open NSS that the time to
recurrence is in mean over 5 years, thus a followup of
o n eo rt w oy e a r s ,w h i c hi sr e p o r t e di nm o s ts e r i e si s
insuﬃcient to show oncological safety [5, 21]. In a recent
meta-analysis on RFA, cryoablation, and surveillance, the
risk of recurrence was 7.45 and 18.23 higher for cryoablation
and RFA, compared to NSS. Additionally this meta-analysis
showed that NSS, ablation, and surveillance are viable
strategies for SRMs based on short-term and intermediate
term oncological outcomes [18]. However, a signiﬁcant
selection bias currently exists in the clinical application
of these techniques with regard to patient age and tumor
size. Although long-term data have demonstrated excellent
outcomes for NSS, extended oncological eﬃcacy remains to
be established for ablation and surveillance strategies. While
current data demonstrate a signiﬁcantly higher incidence of
local tumor progression following cryoablation and RFA,Mehmet Ozsoy et al. 3
no signiﬁcant diﬀerences in progression to metastatic RCC
were seen regardless of treatment modality [18]. These data
suggest an overtreatment bias for SRMs, thus nowadays a
new treatment strategy is “surveillance: treatment by initial
observation with serial imaging with delayed treatment for
progression” gains popularity as a management option for
SRMs.
5. ACTIVE SURVEILLANCE IN WHOM,
HOW AND WHEN?
5.1. Naturalhistory
The natural history of SRM is not well known due to their
early removal after diagnosis in most of the cases. There are
only few insights on the natural history of SRMs.
In one of the important studies regarding surveillance
Bosniak and colleagues retrospectively examined the fol-
lowup images of 40 incidentally detected renal masses
(<3.5cm). After an average of 3.8 years, 26 tumors were
removed. Of these 26 removed masses, 22 (84.6%) were
histologically conﬁrmed as RCC. The overall mean linear
growth rate for all tumors was 0.36cm per year. None of the
patients developed metastasis [22].
In one study, 13 patients with SRM who were either too
old (median patient age was 69 years) or no candidates for
surgery were followed with abdominal imaging for a median
of 42 months. The growth rate was highly variable. Most
SRM grew at a low rate or not at all [23]. In a subsequent
study, 32 renal masses <4cm (25 solid masses, 7 complex
cysts) which were found in 29 patients were managed by
surveillance. During a median followup of 27.9 months
(range: 5.3–143.0 months) serial abdominal imaging was
performed at least three times on each mass. The average
growth rate was low and it did not show any statistical
diﬀerence from zero growth (P=. 09; 95% conﬁdence
interval, −0.005–0.2cm per year) and was not associated
with either initial size (P=. 28) or mass type (P=. 41).
Sevenmasses(22%)reached4cmingreatestdimensionafter
12–85 months of followup. Eight masses (25%) doubled
their volumes within 12 months. Overall, 11 masses (34%)
fulﬁlled one of these two criteria of rapid growth. Nine
tumors were removed surgically after an average of 3.1 years
of followup either due to surgeon’s concern or patient’s
anxiety. No progression to metastatic disease was observed
[24].
There are a certain number of other retrospective studies
investigating the natural history of SRM. Commonly these
authors render surveillance as a possible safe option for
patientswithshort-lifeexpectanciesorpatientswhoareunﬁt
for surgery. Unfortunately these studies accrued a limited
number of patients and had short followup durations [25–
29]. In their review, Rendon and Jewett [30]c o n c l u d ea c t i v e
surveillance as a viable and safe option for the patient with a
short-life expectancy or within well-controlled clinical trials.
They also point out the necessity of close interval followups
using imaging techniques every 3 months for the 1st year,
every 6 months for the next 2 years and once every year
thereafter.
In a meta-analysis by Chawla et al. [8], 234 SRM under
surveillance were included. Mean lesion size at presentation
was 2.60cm (median 2.48, ranging from 1.73 to 4.08).
Lesions were observed for a mean followup of 34 months
(median 32, ranging from 26 to 39 in all series combined).
The mean growth rate was 0.28cm per year (median 0.28,
ranging from 0.09 to 0.86) and only 1% of the patients
developed metastatic disease. In 46% of the cases (131 out
of 286), a pathological conﬁrmation was available, which
showed RCC in 92% (120 of 131). Among RCC, a mean
growth rate of 0.40cm yearly (median 0.35, ranging from
0.42 to 1.6) was observed. Lesion size at presentation did not
correlate with growth rate (P=. 46). Serial radiographic data
a l o n ew e r ei n s u ﬃcient to predict the true natural history of
SRM and patients concomitant diseases should also be taken
into consideration when deciding for active surveillance.
Kouba et al. [31] reported short-term outcomes of
patients under surveillance. A total of 43 patients with 46
renal masses underwent planned expectant management of
enhancing solid or cystic (Bosniak IV) renal masses. 74% of
patients had tumor growth with a mean (median) growth
rate of 0.70 (0.35) cm per year during a mean followup
of 36 months. There were no signiﬁcant symptoms, disease
progression or cancer-speciﬁc death. Four patients (10%)
diedofothercauses.13outof43patientsunderwentsurgical
intervention after a mean delay of 12 months. Initial tumor
size showed no signiﬁcant diﬀerence in the intervention and
nonintervention group (3.1cm 2.6cm, resp., P = .4504) and
there was also no correlation between growth rate and tumor
size.Delayedinterventiondidnotappeartoadverselyimpact
pathological outcomes. The authors consider surveillance
for SRM as a reasonable option for appropriately selected
patients, especially the elderly and those with competing co-
morbidities.
These data suggest that active surveillance is an option
in elderly patients with severe comorbidities or patients,
who are not willing to undergo surgery. Excellent patient
compliance and close followup with contrast enhanced CT
or MRI is mandatory.
5.2. Limitations
Imaging alone is inadequate on deﬁning management in
patients with SRMs. Punnen et al. observed inter- and
intraobserver variability in measuring tumor diameter
(±0.3cm in diameter). Tumor volume is exponentially
related to tumor diameter, and thus inaccuracy of measuring
tumor diameters is related to a greater error (inter- and
intraobserver variability for tumor volume 2.515mm3 and
2.075mm3,r e s p . )[ 32].
5.3. Roleofrenaltumorbiopsy
There have been serious suspicions in the past about needle-
corebiopsiesofrenalmassesregardingcomplications,tumor
seeding,andwrongsampling.Duetoadvancesinapplication
techniques and help of imaging guidance, the results of
needle biopsies have improved signiﬁcantly. Fine-needle
aspiration (18-gauge or thinner) and core biopsies of renal4 Advances in Urology
masses are now much safer than before and they can even
be applied in an outpatient setting with low morbidity rates
[33–36].
Today the success rate of obtaining tissue and their
pathologic interpretation are excellent [37]. Neuzillet et al.
[34] were able to obtain adequate material for histological
examination from 96.6% out of 88 patients that under-
went Helical-CT-guided percutaneous ﬁne-needle biopsy. 62
patients whose biopsy examinations indicated RCCs were
treated surgically (radical or partial nephrectomy). The
postoperative evaluation revealed a 92%-sensitivity rate of
biopsy in predicting malignancy and tumor subtype. The
results also showed no false-positive cases, no track seeding,
and no complications.
Schmidbauer et al. [37] published a prospective study on
78 patients with SRMs who underwent 18-gauge core biopsy
under computed tomography (CT)-ﬂuoroscopic guidance.
In addition, using the same sheath, ﬁne-needle aspiration
wastakenin44patientsandanalyzedcytologically.Therenal
masses were subsequently removed surgically and evaluated
histologically. The results showed a sensitivity of 93.5%
and 90.6%, for core biopsy and ﬁne-needle aspiration for
the detection of renal cell carcinoma (RCC), respectively;
Fuhrman grade was correctly predicted in 76% and 28%
and the correct histologic subtype identiﬁed 91% and 86%,
respectively. Cytology from ﬁne-needle aspiration revealed
a sensitivity of 100% and 75% in detecting malignant and
benign lesions, respectively. Two of the SRMs’ diagnosed
a so n c o c y t o m a so nc o r eb i o p s yw e r er e v e a l e dt ob eh y b r i d
tumors with scattered areas of oncocytomas and chromo-
phobe RCC on histological evaluation.
These data suggest that before opting for surveillance a
suﬃcient renal tumor mass biopsy should be performed to
further guide followup.
6. WHO AND HOW?
According to many authors, active surveillance is a feasible
optionespeciallyforelderlyandunﬁtpatients.Becauseactive
surveillance is a new concept, large studies with appropriate
followup are still missing. Which patients should undergo
active surveillance? What should be our followup intervals?
What is the cut-oﬀ tumor diameter? What should be the
limit for annual growth? In order to precisely answer these
questions, larger numbers of studies are required. In some
centers, renal masses below the limit of 3-4cm in diameter
are considered to be at low risk of metastasis [38, 39].
The authors believe that low-grade tumors measuring
<3cm could enter an active surveillance protocol. Prior
and during followup, renal tumor biopsies are mandatory.
Biopsies should be assessed by the same pathologist to
exclude interobserver variations, especially in grading. High-
grade tumors, sarcomatoid features, collecting duct, and
unclassiﬁed RCC have to be excluded because of their known
unfavorable outcomes. Additionally, young and/or healthy
patients are no good candidates for active surveillance
because of lacking long-term data (see Table 1).
For followup, Rendon et al. suggested CT or MRI every
3 months in the 1st year, every 6 months for the next 2
Table 1: Possible inclusion and exclusion criteria for active sur-
veillance of SRM.
Inclusion:
(1) Benign lesion on renal tumor biopsy
(2) Aged and inﬁrm patient
(3) Tumor size <3cm on cross-sectional imaging
(4) Chromophobe RCC, low-grade, on renal tumor biopsy
(5) Chromophobe-oncocytic hybrid tumor on renal tumor biopsy
(6) Willingness of the patient to undergo regular CT or MRI scans
and repeated biopsies (good compliance)
Exclusion:
(1) Young and healthy patient
(2) Sarcomatoid features
(3) Collecting duct or unclassiﬁed RCC
(4) Evidence of ≥T3a disease on cross-sectional imaging
(5) High grade
(6) Symptomatic lesions
Unclear:
(1) Low grade clear-cell RCC
(2) Low-grade papillary RCC
(3) Multifocal RCC
(4) Hereditary RCC
years and every year thereafter [30], however, there are no
oncological outcome data that support this approach. Again,
repeated biopsies of the mass have to be performed in certain
intervals. Tumors that exceed 3 or 4cm or which double in
volume in <12 months need further intervention [7, 10, 11],
for example, surgery or ablation.
These short-interval followups may have a negative
impact on patient compliance. Another downside of active
surveillance is the patient’s anxiety. The knowledge of living
with a tumor and “not doing anything about it” is also a
psychological burden on the patient.
7. CONCLUSIONS
Active surveillance is a new management option for the aged
and inﬁrm patient with short-life expectancy. The current
literature contains mostly small, retrospective studies with
limiteddata.Priorandduringfollowup,renaltumorbiopsies
are mandatory. Thus, the authors rather believe in active
surveillance than in classical observation. Imaging alone is
inadequateforsuggestingtheaggressivepotential ofSRMfor
both diagnosis and followup. Current data suggest that a CT
or MRI every 3 months in the 1st year, every 6 months in
the next 2 years and every year thereafter, is appropriate for
observation.
Since not all SRM are harmless, selection criteria for
active surveillance need to be improved. In addition, there is
need for larger studies in order to better outline oncological
outcome and followup protocols.
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